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A Case of Pyoderma Gangrenosum
Christopher T. Miller, MD

Case Report
A 60-year-old man with past medical history of hypertension,
post-traumatic stress disorder, major depression, hepatic
steatosis, chronic kidney disease, and untreated hepatitis C virus
(genotype 1b) initially presented to the outpatient primary care
clinic with a chief complaint of an extremely painful right lower
extremity ulcer that had developed and grown progressively
larger after mild trauma against a metal corner 4 months prior
to the appointment. He admitted to picking at the granulation
tissue that would develop over the ulcer. He was treating the
ulcer with antibiotic ointment. On initial exam, the ulcer was
about 2x2 cm, located a few inches above the ankle on the lateral
right leg, and associated with some lower extremity edema. His
primary care physician was concerned at the time for a venous
stasis ulcer. Initial plain films of the leg were obtained, and these
did not show any evidence of osteomyelitis. A lower extremity
doppler ultrasound did not reveal a deep vein thrombosis that
could account for the edema. He had no signs of heart failure,
ascites, or volume overload otherwise. He was referred to
podiatry and wound care.
The patient was assessed by podiatry about 2 weeks later. The
podiatrist noted mycotic toenail infection on both feet, mild 1+
edema, and noted that the lesion had a small eschar. He also felt
the wound was a venous stasis ulcer and recommended daily
collagenase covering for enzymatic wound debridement.
The patient was subsequently seen over the next few weeks at
wound care clinic. There, the ulcer was noted to have a bit of
sloughing material which was removed with scissors each time.
The wound did not clinically appear infected at any of these
appointments. The patient noted worsening pain with each
mechanical debridement.
The patient was seen by surgery who also initially felt the
patient had a vascular ulcer. Compression wrappings and
Dermagraft were employed as treatment. The patient had an
ankle-brachial index calculated with ultrasound. The results
of this study were normal. An arteriogram of the extremity
was roughly normal. Surgery noted that with each mechanical
debridement, that patient returned to clinic in more pain with
more necrotic material, and the ulcer increased in size and
depth with each appointment.
The possibility of pyoderma gangrenosum was eventually
considered by surgery. A biopsy of the ulcer was performed,
and the patient was referred to rheumatology about 7 months
after initial presentation. His wound appeared significantly
more edematous and inflamed after the biopsy. A tendon
was found to be exposed at the wound base in rheumatology
clinic. The patient was tested for vasculitis, but was negative
for cryoglobulins, rheumatoid factor, and anti-neutrophil
cytoplasmic antibodies (ANCAs). Biopsy results were consistent
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with pyoderma gangrenosum. He was started on prednisone,
but the wound became foul-smelling. The patient was directly
admitted to the inpatient medicine floors after a rheumatology
follow-up exam and was started on antibiotics. He was seen as an
inpatient by an infectious disease specialist and was diagnosed
with cellulitis.
The patient was successfully treated for the cellulitis with a course
of antibiotics. Dermatology was consulted and felt the biopsy
results in addition to history of wound pathergy (worsening
lesion with mechanical manipulation or mild trauma) was
consistent with a diagnosis of pyoderma gangrenosum.
The overall concern of the medical team was that his exposed
tendon would become infected and track infection to other
areas of the leg. The team felt the tendon should be excised,
but there was concern further debridement could lead to
further wound pathergy. The consensus was that he should be
sufficiently immune-suppressed before surgical therapy, then
have the tendon removed before attempting possible skin graft.
The patient was continued on steroids. He was also considered
for concurrent cyclosporine; however, he was deemed to not
be a candidate secondary to decreased renal function. He
was considered for infliximab as a second-line treatment.
Incidentally, the patient had had close contact with a relative
with active tuberculosis (TB) within the past 5 years, so there
was concern that infliximab could precipitate reactivation
of latent tuberculosis. Although he had a negative purified
protein derivative (PPD) test, the patient was on corticosteroids, and the infectious disease team felt the likelihood of a
false-negative in this setting was high. He was therefore started
on empiric isoniazid for latent TB infection and was to begin
infliximab 1 month into this treatment. He was to follow up
with rheumatology and surgery. To date, his wound appears to
be accumulating granulation tissue indicating recovery after a
single infusion of infliximab.

Discussion
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis
that causes skin papules or vesicles that eventually progress to
ulcerations. Lesions are usually located on the lower extremities
and are often multiple in number. Ulcerations are painful (pain is
usually out of proportion to exam) and generally have a purulent
base with rough, violaceous border. Tendons and muscles can
become exposed in the wound. Wounds can demonstrate
pathergy, or wound exacerbation with mechanical manipulation.
The pathophysiology of PG is incompletely understood. A
better understanding may come with further study of the
inflammasome. Inflammasomes are intracellular macromolecules that sense foreign or pathologic material and cause
39
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cellular release of “warning” mediators. Their study has led to
a better understanding of a multitude of familial autoimmune
diseases. One particular mutation to the proline-serinethreonine phosphatase interacting protein1 (PSTPIP1) gene
has been associated with PAPA (pyogenic arthritis with
pyoderma gangrenosum and acne syndrome). Mutations in
PSTPIP1 are believed to cause increased interaction with the
molecule pyrin. The exact signaling cascade of this interaction
is not yet certain, however, the consequence appears to be
increased release of the inflammatory mediator IL-1β. Targeted
therapies against IL-1β, however, have only been reported in
limited anecdotal accounts, so the PSTPIP1 mutation may
cause additional consequences that are not yet known.
PG is associated with systemic disease in 50% or more of
cases. (Debade et al 2011) Examples include inflammatory
bowel disease (IBD), rheumatoid arthritis (RA), and acute
myeloblastic leukemia (AML) or lymphoproliferative disease
(PG can sometimes be a paraneoplastic disorder in these cases).
It can also occur in idiopathic cases.
PG can be classified into 4 different subtypes based on clinical
presentation and histopathology: ulcerative, pustular, bullous,
and vegetative. Patients typically present with one subtype of PG.
Ulcerative PG is characterized clinically by ulcers with eroded
borders and surrounding inflammation and histologically
by centrally neutrophilic abscess and marginal lymphocytic
angiocentric infiltrates. This disease subtype generally presents
with progression of small papules into the aforementioned
ulcerations, which can be fatal in its most severe form.
Pustular PG has clinical findings of inflammatory pustules
(measuring less than 8mm) and dense neutrophilic infiltrates
in perifollicular, follicular, and dermal zones on histology. It is
often associated with IBD flares. This disease subtype generally
manifests similarly to the ulcerative subtype, but does not
progress to such a severe extent.
Bullous PG has a clinical presentation of superficial painful,
sometimes inflamed bullae that can progress to ulcers.
Histologically it appears as a subepidermal bulla with intraepidermal and dermal neutrophils. It often heralds a poor prognosis
if associated with hematologic malignancy.
Vegetative PG is characterized by a painless single shallow
ulcer with slow progression. It shows pseudoepitheliomatous
hyperplasia, dermal neutrophilic abscess, sinus tracts, and
palisading granulomas on histology. It is usually associated with
idiopathic cases. It is generally nonaggressive.
Differential diagnoses for PG include vascular insufficiency,
atypical mycobacterium, fungal infection, spider or insect
bite, vasculitis, gummatous syphilis, gangrene, drug reaction,
malignancy, antiphospholipid syndrome, amebiasis, halogenodermas (superficial reaction to halogen compounds), factitial
disorder, and viral infection (like Herpes simplex virus).
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Diagnosis is established by history and biopsy consistent with
PG, and exclusion of other disorders.
Treatment for PG is generally based on case reports and expert
opinion, as so few cases have been diagnosed and documented
that only one double-blinded, randomized study exists to date.
For the purposes of this case report, a treatment algorithm
suggested in early 2011 in Dermatologic Therapy has been
referenced as one of the most up-to-date references. The
algorithm consists of both local and systemic therapy. Local
therapy alone may be considered in mild cases. Local treatments
include topical immunosuppressants such as corticosteroids
(clobetasol) or tacrolimus. Numerous dressing types can
be applied with a goal of a moist, but not overtly wet or dry
lesion. Mechanical or chemical debridement is contraindicated
due to pathergy. Systemic treatment, generally with corticosteroids, is first line therapy in most cases of PG. Although
experts generally consider steroids the first line therapy, no
randomized, double-blind trials exist to support their use.
Prednisone is commonly used and is historically initiated at
1-2mg/kg. During initiation of therapy, underlying systemic
disease like IBD or RA should be treated as well if uncontrolled.
This can often lead to improvement in PG, although treatment
specifically targeted at PG should continue, as flares of PG and
systemic disease may occur independently despite coexistence
in a single patient. After treatment initiation, improvement
of wound pain, decrease in the violaceous appearance of the
wound, and flattening of wound borders indicates healing. No
new lesions should appear if the disease process is adequately
controlled. At this point, steroid tapering should be considered.
A steroid-sparing agent may be added if there is any recurrence.
In refractory cases of PG, diagnostic steps should be reviewed
or even repeated to determine if the diagnosis of PG is correct.
If diagnosis is felt to be certain, steroids should be pulsed or a
second-line therapy added. The aforementioned assessment of
healing and disease control remains a guidepost to determine
when immunosuppressants can be tapered. Second-line
treatments are numerous. Cyclosporine is one of the most
widely used agents, as it is historically backed by some of the
most literature amongst treatments. Infliximab, an anti-TNF
immunomodulator, is the only PG treatment to date that
has been examined in a randomized, double-blinded study. 1
Published in 2006 by Brooklyn et al, this 30-patient study
compared infliximab to placebo and was found to be superior,
even in patients without known underlying concurrent disease
(although this study did not compare infliximab head-to-head
with first line therapy like steroids or cyclosporine). Other
second-line systemic treatments that have been described
include methotrexate, azathioprine, cyclophosphamide,
mycophenolate mofetil, tacrolimus, dapsone, chlorambucil,
IVIG, colchicine, interferon alpha, etanercept, adalimumab,
and alefacept. The use and efficacy of these therapies is largely
anecdotal. Hyperbaric oxygen, skin grafting, and plasmapheresis are amongst additional tertiary therapies that have
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been described and may be considered as concurrent therapy to
the algorithm suggested above. Consensus expert opinion has
generally advised against surgical intervention, however, when
necessary, it should be postponed until sufficient immunosuppression and disease control has been established.

Conclusion
PG is a rare, painful, ulcerating skin disorder that often affects
the lower extremities. The lesions can demonstrate pathergy and
may be associated with an underlying systemic disease such as
IBD, RA, or various hematologic disorders. Diagnosis is based
on clinical history, biopsy, and exclusion. Treatment consists of
local topical immunosuppressants and wound care, avoidance
of debridement, and usually systemic corticosteroids. Treatment
failure or relapse is treated with a second-line agent such as
cyclosporine or infliximab, usually in conjunction with corticosteroids. Infliximab is the only therapy that has demonstrated
efficacy in a randomized, double-blinded, placebo-controlled
trial, although significant literature exists to support the use of
corticosteroids, cyclosporine, and many other agents. Surgical
intervention should only be considered if adequate therapy has
been established by symptoms and signs of decreasing pain,
decreased wound discoloration, wound margin flattening, and
lack of appearance of new lesions.

Our patient in this case had a history and biopsy consistent
with PG. His wound demonstrated pathergy and continued to
worsen as aggressive mechanical debridement was pursued
under the assumed diagnosis of venous insufficiency. When
the diagnosis was established, he did not initially respond to
steroids. Investigation for other systemic diseases was unfruitful.
He was deemed to not be a candidate for cyclosporine due to
compromised renal function, so infliximab was added instead.
He appears to be responding to this combined treatment regimen.
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